Midterm Response with Latanoprost Therapy in German Ocular Hypertension Patients

REFERENCES

• Gordon M O, Beiser J A, Brandt J D, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120: 714–720
   PubMed Web of Science ®Google Scholar
• Book S A. Essentials of statistics. Testing Statistical Hypotheses, A A Arthur, J Rogers, J W Bradley. McGraw-Hill, New York 1978; 117–122
   Google Scholar
• Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning: a comparison with timolol. Ophthalmology 1995; 102: 1743–1752
   PubMed Web of Science ®Google Scholar
• Camras C B. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month, masked, multicenter trial in the United States. Ophthalmology 1996; 103: 138–147
   PubMed Web of Science ®Google Scholar
• Hedman K, Larsson L I. The effect of latanoprost compared with timolol in African-American, Asian, Caucasian, and Mexican open-angle glaucoma or ocular hypertensive patients. Surv Ophthalmol 2002; 47: S77–S89
   PubMed Web of Science ®Google Scholar
• Stewart W C, Day D G, Stewart J A, et al. The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001; 131: 631–635
   PubMed Web of Science ®Google Scholar
• Orzalesi N, Rossetti L, Bottoli A, et al. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Arch Ophthalmol 2003; 121: 453–457
   PubMed Web of Science ®Google Scholar
• Fechtner R D, Realini T. Fixed combinations of topical glaucoma medications. Curr Opin Ophthalmol 2004; 15: 132–135
   PubMedGoogle Scholar
• Konstas A GP, Papapanos P, Tersis I, et al. Twenty-four hour diurnal curve comparison of commercially available latanoprost 0.005% versus timolol/dorzolamide fixed combination. Ophthalmology 2003; 110: 1357–1360
   PubMed Web of Science ®Google Scholar
• Dubiner H, Cooke D, Dirks M, et al. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Surv Ophthalmol 2002; 45: S353–S360
   Google Scholar
• Netland P A, Landry T, Sullivan E K, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001; 132: 472–484
   PubMed Web of Science ®Google Scholar
• Noecker R S, Dirks M S, Choplin N T, et al. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 2003; 135: 55–63
   PubMed Web of Science ®Google Scholar
• Parrish R K, Palmberg P, Sheu W P. XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003; 135: 688–703
   PubMed Web of Science ®Google Scholar
• Konstas A GP, Katsimbris J M, Lallos N, et al. Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients. Ophthalmology 2005; 112: 262–266
   PubMed Web of Science ®Google Scholar
• Alm A, Schoenfelder J, McDermott J. A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma. Arch Ophthalmol 2004; 122: 957–965
   PubMed Web of Science ®Google Scholar
• Albert D M, Gangnon R E, Zimbric M L, et al. A study of iridectomy histopathologic features of latanoprost-and non-latanoprost-treated patients. Arch Ophthalmol 2004; 122: 1680–1685
   PubMedGoogle Scholar
• Schumer R, Camras C, Madahl A. Putative side effects of prostaglandin analogs. Surv Ophthalmol 2002; 47: S219
   Web of Science ®Google Scholar
• Stewart W C. How the new prostaglandins stack up: a look at what clinical studies reveal about travoprost and bimatoprost in relation to latanoprost. Rev Ophthalmol 2002; 9: 58
   Google Scholar
• Bayer A, Weiler W, Oeverhaus U, et al. Two-year follow-up of latanoprost 0.005% monotherapy after changing from previous glaucoma therapies. J Ocul Pharmacol Ther 2004; 20: 470–478
   PubMed Web of Science ®Google Scholar
• Watson P G. Latanoprost. Two years' experience of its use in the United Kingdom. Latanoprost Study Group. Ophthalmology 1998; 105: 82–87
   PubMed Web of Science ®Google Scholar
• Mao L K, Stewart W C, Shields M B. Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma. Am J Ophthalmol 1991; 111: 51–55
   PubMed Web of Science ®Google Scholar
• Stewart W C, Chorak R P, Hunt H H, Sethuraman G. Factors associated with visual loss in patients with advanced glaucomatous changes in the optic nerve head. Am J Ophthalmol 1993; 116: 176–181
   PubMed Web of Science ®Google Scholar
• Stewart W C, Kolker A E, Sharpe E D, et al. Factors associated with long-term progression or stability in primary open-angle glaucoma. Am J Ophthalmol 2000; 130: 274–279
   PubMed Web of Science ®Google Scholar
• Konstas A G, Hollo G, Astakhov Y S, et al. Factors associated with long-term progression or stability in exfoliation glaucoma. Arch Ophthalmol. 2004; 122: 29–33
   PubMed Web of Science ®Google Scholar
• Grant W M, Burke J F. Why do some people go blind from glaucoma?. Ophthalmology 1982; 89: 991–998
   PubMed Web of Science ®Google Scholar
• Kolker A E. Visual prognosis in advanced glaucoma: a comparison of medical and surgical therapy for retention of vision in 101 eyes with advanced glaucoma. Trans Am Ophthalmol Soc. 1977; 75: 539
   PubMedGoogle Scholar
• The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000; 130: 429–440
   PubMed Web of Science ®Google Scholar
• Stewart W C. Clinical Practice of Glaucoma. SLACK, Inc., Thorofare, NJ 1990
   Google Scholar
• Haverkamp F, Wuensch S, Fuchs M, Stewart W C. Intraocular pressure, safety and quality of life in glaucoma patients switching to latanoprost from adjunctive and monotherapy treatments. Eur J Ophthalmol 2004; 14: 407–415
   PubMed Web of Science ®Google Scholar
• Day D G, Schacknow P N, Sharpe E D, et al. A persistency and economic analysis of latanoprost, bimatoprost or beta-blockers in patients with open-angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther 2004; 20: 383–392
   Google Scholar
• Diestelhorst M, Schaefer C P, Beusterien K M, et al. Persistency and clinical outcomes associated with latanoprost and beta-blocker monotherapy: evidence from a European retrospective cohort study. Eur J Ophthalmol. 2003; 13: 21–29
   PubMed Web of Science ®Google Scholar